January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

Co., Inc. (NYSE: MRK) has initiated a pivotal Phase 3 clinical trial, waveLINE-010, to evaluate the efficacy of its investigational drug zilovertamab vedotin in treating patients with previously ...

William Blair initiated coverage on Mersana Therapeutics, Inc. (NASDAQ:MRSN) with an Outperform rating. The firm's analyst cited the company's potential in the antibody-drug conjugates (ADCs) market ...

Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ('CSPC') (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Trials in China usually recruit patients faster than in the west because of the country’s large pool of people who have not yet taken drugs for their condition and who are keen to participate in ...

Antibody Drug Conjugates Market Market Growth Fueled by Advancements in ADC Technology, Increased Demand for Targeted Cancer Therapies, and ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell.

Corbus Pharmaceuticals Holdings, Inc.’s CRBP share price has surged by 17.41%, which has investors questioning if this is right time to sell.

The increasing global prevalence of cancer is fueling the demand for peptide-drug conjugates as targeted therapies, providing improved effectiveness and lower systemic toxicity than conventional ...

DelveInsight's Peptide-drug Conjugate Market Insights report provides the current and forecast market analysis, individual ...

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

A new study shows how an anticancer drug triggers an "outside in" signal that gets it sucked into a cancer cell. The work, published Jan. 29 in Nature Communications, reveals a new signaling mechanism ...